Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.
about
Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated ratsCCR2 modulates inflammatory and metabolic effects of high-fat feedingNLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis.In vivo imaging implicates CCR2(+) monocytes as regulators of neutrophil recruitment during arthritisThe obesity and inflammatory marker haptoglobin attracts monocytes via interaction with chemokine (C-C motif) receptor 2 (CCR2).Induced Pluripotent Stem Cell-Derived Endothelial Cells Overexpressing Interleukin-8 Receptors A/B and/or C-C Chemokine Receptors 2/5 Inhibit Vascular Injury ResponseThe journey from stem cell to macrophage.Insights into the regulation of chemokine receptors by molecular signaling pathways: functional roles in neuropathic painCCR2 plays a critical role in dendritic cell maturation: possible role of CCL2 and NF-kappa B.Suppression and regression of choroidal neovascularization in mice by a novel CCR2 antagonist, INCB3344Discrepancy in CCL2 and CCR2 expression in white versus grey matter hippocampal lesions of Multiple Sclerosis patients.Role of CCR2 in inflammatory conditions of the central nervous system.Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody-mediated arthritis in a murine modelElevated CXCL1 expression in breast cancer stroma predicts poor prognosis and is inversely associated with expression of TGF-β signaling proteinsTargeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors.Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E-/- miceChemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cellsDiscovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 functionInflammation, endoplasmic reticulum stress, autophagy, and the monocyte chemoattractant protein-1/CCR2 pathway.Low-dose TNF augments fracture healing in normal and osteoporotic bone by up-regulating the innate immune response.Temporal expression and cellular origin of CC chemokine receptors CCR1, CCR2 and CCR5 in the central nervous system: insight into mechanisms of MOG-induced EAE.Modified huo-luo-xiao-ling dan suppresses adjuvant arthritis by inhibiting chemokines and matrix-degrading enzymes.Monocyte Chemoattractant Protein 1 (MCP-1) in obesity and diabetesSuppression of autoimmune arthritis by Celastrus-derived Celastrol through modulation of pro-inflammatory chemokinesThe CCL2 synthesis inhibitor bindarit targets cells of the neurovascular unit, and suppresses experimental autoimmune encephalomyelitis.An engineered monomer of CCL2 has anti-inflammatory properties emphasizing the importance of oligomerization for chemokine activity in vivo.Molecular targets for disrupting leukocyte trafficking during multiple sclerosis.Role of macrophages in complications of type 2 diabetes.Chemokines and chemokine receptors in neurological disease: raise, retain, or reduce?Chemokines: a new class of neuromodulator?CCR2-antagonist prophylaxis reduces pulmonary immune pathology and markedly improves survival during influenza infection.Future therapeutic treatment of COPD: struggle between oxidants and cytokinesChemokines and pain mechanisms.CCR2 and CXCR4 regulate peripheral blood monocyte pharmacodynamics and link to efficacy in experimental autoimmune encephalomyelitis.Chemokines as possible targets in modulation of the secondary damage after acute spinal cord injury: a review.Chemokine receptor antagonists: Part 1.Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists.Targeting lung inflammation: novel therapies for the treatment of COPD.Anti-chemokine small molecule drugs: a promising future?Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases.
P2860
Q28577588-2CB9621E-772A-4613-BB8A-F4DE0B96BFD4Q29622869-05CED344-DE12-4FB1-9EF9-D58DFC11B076Q30519470-99A398DF-3167-43C1-9812-C995447610B1Q30543940-E8C2F6F3-4A60-4A04-9C78-5C4C4EB38456Q33519162-C50B6E3C-9B30-4512-AD25-D2E8327C7015Q33722663-DFD62EA3-49F4-4601-9ECA-743BEBA7DE8DQ33817936-162EACEF-15EC-4E93-9CB9-0E3FBE4F279DQ33965479-6C4955B0-FB4F-432D-A05D-545C30B82B9CQ34091124-3FAF32E9-83E2-4DBB-906D-0729527536E9Q34113663-06949546-9CF7-44E0-ADDA-3D75822F4627Q34151104-7DFB0FEF-9F60-4B94-857E-B0FCFD1C65C4Q34153471-4368283E-EEBA-4936-917F-FF7C20A36101Q34365089-110C28E5-1B6E-4A88-914D-9937921DEF92Q34460058-D5C010F7-1951-4A52-896A-8313B2FA6F9FQ34550440-F0DEBDF6-5C42-49C1-8BBE-0144412CA539Q34993425-BA92FBB5-B346-4185-A16F-BD3CBD6CA928Q35011812-A5AB63E0-BD84-4144-AB80-48E599EE8FB8Q35588337-5CFDCA66-7F0C-482E-82E8-0A1BD5530029Q35691449-A610DA36-E7AE-4E78-ADC7-F270FA8E45B1Q35822559-A1D3CEDA-10F4-451E-BE1C-9A197F492D10Q35825040-8B98AF3C-53A4-4409-9D4E-249161AA64C5Q35846225-B8B3690F-CEA3-4DA9-95FF-1E7EED3E394BQ36222092-5F217EF7-76CF-47E5-A55A-08EA661E00F9Q36253492-47992B48-99A8-4FAB-B195-F94A441CCFC0Q36371175-FA87391A-17D4-4FBE-A05D-2730127CF1A0Q36882279-6125A202-CCC1-4075-A76F-2CD8A9866813Q36885184-1A0BBE96-8741-4EA5-A851-211D66E7DFFFQ36916949-804BD195-DFF5-4BCB-B5C7-38530F218AB1Q36963161-AEBFE1FC-BF37-4E56-B394-7A917CF814EEQ36975766-26FB95EE-8534-4ED1-93A0-39E3934CF660Q37045180-B0E40A2B-1DC2-46B7-9432-D4CE258A01E3Q37071004-FB7C97E5-6ACC-4A69-ADEC-327FA145E27CQ37215729-44A3B24B-3509-4CDA-9CB9-10EB2A20CBADQ37422455-88F97A9A-F294-4EFB-B391-E5F1EA08602CQ37442685-E9F63212-19A1-406E-94FE-9A3E43628F51Q37481238-27BAF613-FB64-46C9-9AFE-8CB229D6863EQ37507076-0BBFE15A-BF63-4129-889C-FF7A8709F419Q37578310-968E5BA9-3391-4772-88B4-4CE39B8D50F9Q37683772-5A3097F3-2C8A-4202-80B8-7EDB8480FE12Q37723178-25EE35DD-325F-4FDF-A4A4-059C1D7B00B4
P2860
Discovery and pharmacological characterization of a novel rodent-active CCR2 antagonist, INCB3344.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Discovery and pharmacological ...... ive CCR2 antagonist, INCB3344.
@en
type
label
Discovery and pharmacological ...... ive CCR2 antagonist, INCB3344.
@en
prefLabel
Discovery and pharmacological ...... ive CCR2 antagonist, INCB3344.
@en
P2093
P1476
Discovery and pharmacological ...... ive CCR2 antagonist, INCB3344.
@en
P2093
Anlai Wang
Beth Thomas
Carrie M Brodmerkel
Chu Biao Xue
Frederic Baribaud
Greg Hollis
Karen Gallagher
Kim Solomon
Kris Vaddi
Leslie Hall
P304
P356
10.4049/JIMMUNOL.175.8.5370
P407
P577
2005-10-01T00:00:00Z